Cytosurge AG
Based on the patented FluidFM technology, Cytosurge AG provides the unique FluidFM BOT system that optimizes CRISPR-Cas transfection by delivering CRISPR-Cas9 complexes directly to where they are required: the nucleus. This is made possible by the FluidFM nanosyringe, which is with its 500 nm aperture probably the world’s smallest syringe. It is ideal for nano-injecting into difficult to transfect cells such as hiPS, neurones and even recently cardiomyocytes.
In addition to nano-injection, the cutting-edge FluidFM BOT system can also perform other unique applications such as single cell isolation and nano-printing.
Seeing is believing – We look forward to meeting you at our booth and discussing how we could help you to optimize your CRISPR experiments.